Statement Of Cash Flows [Abstract]

OSE Immunotherapeutics - Filing #831399

Concept 2023-01-01 to
2023-12-31
As at
2023-12-31
2023-01-01 to
2023-12-31
As at
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
As at
2021-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Profit (loss)
23 003 EUR
23 003 EUR
17 760 EUR
17 760 EUR
Adjustments to reconcile profit (loss) [abstract]
Adjustments for income tax expense
219,000 EUR
263,000 EUR
Adjustments for decrease (increase) in trade accounts receivable
578,000 EUR
Adjustments for increase (decrease) in trade accounts payable
759,000 EUR
Adjustments for depreciation and amortisation expense
2 679 EUR
2 795 EUR
Adjustments for provisions
91,000 EUR
198,000 EUR
Adjustments for share-based payments
1 746 EUR
2 728 EUR
Cash flows from (used in) operations
18 714 EUR
14 874 EUR
Income taxes paid (refund), classified as operating activities
0 EUR
0 EUR
Cash flows from (used in) operating activities
19 764 EUR
18 252 EUR
Cash flows from (used in) investing activities [abstract]
Cash flows from (used in) investing activities
507,000 EUR
26,000 EUR
Cash flows from (used in) financing activities [abstract]
Proceeds from issuing shares
11 357 EUR
0 EUR
Proceeds from borrowings, classified as financing activities
5 023 EUR
12 056 EUR
Repayments of borrowings, classified as financing activities
2 719 EUR
1 010 EUR
Payments of lease liabilities, classified as financing activities
637,000 EUR
785,000 EUR
Interest paid, classified as financing activities
0 EUR
0 EUR
Other inflows (outflows) of cash, classified as financing activities
0 EUR
0 EUR
Cash flows from (used in) financing activities
13 324 EUR
10 267 EUR
Effect of exchange rate changes on cash and cash equivalents [abstract]
Effect of exchange rate changes on cash and cash equivalents
0 EUR
0 EUR
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes
6 948 EUR
7 959 EUR
Cash and cash equivalents
18 672 EUR
25 620 EUR
33 579 EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.